Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Michael Sand, Ruhr University of Bochum
ClinicalTrials.gov Identifier:
NCT01500954
First received: December 23, 2011
Last updated: October 15, 2012
Last verified: October 2012
  Purpose

MicroRNAs (miRNAs) are a novel class of short RNAs which have shown to be dysregulated in a variety of cancers. Data of miRNA expression in cutaneous squamous cell carcinoma (cSCC) is very limited and microarray based genome wide miRNA expression profiles of cSCC have not been investigated so far.


Condition
Cutaneous Squamous Cell Carcinoma

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Microarray Analysis of microRNA Expression Profiles in Cutaneous Squamous Cell Carcinoma

Further study details as provided by Ruhr University of Bochum:

Biospecimen Retention:   Samples With DNA

cutaneous squamous cell carcinoma (SCC) non.lesional skin


Enrollment: 7
Study Start Date: October 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
squamous cell carcinoma
non-lesional skin

Detailed Description:

Patients with cutaneous SCC were enrolled in the present study. Tumor biopsies were taken from the center of the tumor. Adjacent healthy skin was biopsied as a control (intraindividual control). miRNA expression profiles of specimen were detected by microarray miRNA expression profiling. Microarray results were confirmed by TaqMan real-time quantitative polymerase chain reaction (RT-PCR).

  Eligibility

Ages Eligible for Study:   1 Year and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with cutaneous squamous cell carcinoma

Criteria

Inclusion Criteria:

  • cutaneous squamous cell carcinoma

Exclusion Criteria:

  • other skin cancer than cutaneous squamous cell carcinoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01500954

Locations
Germany
Department of Dermatology, Venereology and Allergology, Dermatologic Surgery Unit, Ruhr-University Bochum
Bochum, NRW, Germany, 44791
Sponsors and Collaborators
Ruhr University of Bochum
Investigators
Study Director: Falk G Bechara, PD Dr. Department of Dermatology, Venereology and Allergology, Dermatologic Surgery Unit, Ruhr-University Bochum
Study Chair: Peter Altmeyer, Prof. Dr. Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum
Principal Investigator: Michael Sand, Dr. Department of Dermatology, Venereology and Allergology, Dermatologic Surgery Unit, Ruhr-University Bochum
  More Information

Publications:
Responsible Party: Michael Sand, Principal Investigator, Ruhr University of Bochum
ClinicalTrials.gov Identifier: NCT01500954     History of Changes
Other Study ID Numbers: microRNA7
Study First Received: December 23, 2011
Last Updated: October 15, 2012
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Squamous Cell
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell

ClinicalTrials.gov processed this record on November 25, 2014